Lung Cancer - Chemotherapy

JANS Article

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

November 10, 2023 | Aristotle ProtopapasGold Commentor

A manuscript that wil certainly be discussed in lung MDT! The thought of a RCT in these earlier stages may be already in the mind of the sponsors… The authors do not report synergic side...

JANS Article

Underutilization of Systemic Therapy in Patients with NSCLC Undergoing Pneumonectomy: A Missed Opportunity for Survival

September 15, 2023 | Mujtaba MubashirGold Contributor

This large-scale analysis of the National Cancer Database (NCDB) highlights some interesting trends in the current use of systemic therapy in patients with NSCLC who undergo pneumonectomy. Current practice patterns...

JANS Article

The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and Multidisciplinary Management of Patients with Early-Stage Non-Small Cell Lung Cancer

June 15, 2023 | Cameron LindSilver Contributor

A new expert consensus on diagnosis, staging, and therapy for early-stage non-small cell lung cancer patients has been released. The experts recommend CT and PET imaging as a necessary part...

JANS Article

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

May 26, 2022 | Aristotle ProtopapasGold Commentor

No statistical significance ,between the two arms, regarding the OVERALL survival in this RCT funded by the supplier and manufacturer of the immunotherapy in question….

...
JANS Article

Lung Cancer in France

January 27, 2021 | Aristotle ProtopapasGold Commentor

An open-access detailed editorial from the official periodical of the International Association for the Study of Lung Cancer

...
JANS Article

Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer

November 21, 2020 | Aristotle ProtopapasGold Commentor

A scholarly and sober narrative review on , as the authors state, a ‘ hot topic’ that is already being debated in Multidisciplinary Meetings and Lung Cnacer Boards.

...
JANS Article

Year in Review: Lung Cancer

November 7, 2019 | Mark FergusonBronze Contributor

This brief overview of recently presented improvements in lung cancer therapy highlights the substantial benefits of newer chemotherapy and immunotherapy regimens that are transforming the outlooks of many patients with...

JANS Article

A Year at the Forefront of General Thoracic Surgery

April 17, 2019 | Wei-Guo Ma

Dr Burt gives a brief overview of the considerable advances for patients with thoracic malignancies (non–small cell lung cancer in particular).

...
JANS Article

Aggressive Radiotherapy, Surgery Doubles Overall Survival in Non-Small Cell Lung Cancer With Limited Mets

October 23, 2018 | Mark FergusonBronze Contributor

Forty-nine patients with limited metastatic non-small cell lung cancer (three or fewer metastatic sites) who did not progress on initial systemic therapy were randomized to surgery or RT vs standard...

JANS Article

Adding Radiotherapy to Adjuvant Chemotherapy Does Not Improve Survival of Patients With N2 Lung Cancer

October 11, 2018 | Emily RobinsonBronze Contributor

This analysis of the National Cancer Database included over 2000 eligible patients resected with N2 disease who did not receive induction therapy. The addition of radiotherapy to postoperative chemotherapy did...

JANS Article

Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC

September 25, 2018 | Mark FergusonBronze Contributor

This comprises the eagerly anticipated summary of the second primary endpoint of the PACIFIC trial of Durvalumab vs placebo in patients who completed CT/RT without progression for unresectable stage III...

JANS Article

In Global News: Early Menopause From Chemotherapy, Cardiovascular Disease Risk App, and New ESC/EACTS Guidelines

August 31, 2018 | Emily RobinsonBronze Contributor

Patient Care and General Interest Late-breaking results from the VISION study just presented at the European Society of Cardiology’s 2018 annual Congress suggest that 75% of patient deaths after noncardiac...

JANS Article

Nivolumab Plus Ipilimumab in Lung Cancer With a High Tumor Mutational Burden

May 31, 2018 | Mark FergusonBronze Contributor

This randomized trial evaluating the relative efficacy of immunotherapy and chemotherapy in patients with recurrent or metastatic disease, immunotherapy was associated with significantly better progression-free survival. Tumor mutational burden was...

LOAD MORE
ADVERTISE ON CTSNET